ArticleHealth economics review2025
Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027.
Article in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveIn recent years, spending on orphan drugs in Italy has seen a significant rise. The analysis aims to estimate future spending for medicines for rare diseases (RDs) in Italy.
methodsA forecasting model was developed over a three-year time frame. New drugs were selected according to specific criteria, using Biomedtracker and clinical trial databases. For each therapeutic indication, comparators were identified to estimate the average cost per patient. Overall expenditure was projected by applying prevalence data to the eligible population, and considering expected drug uptake trends over the study period. Additionally, a deterministic sensitivity analysis was performed to assess the influence of price fluctuations on total pharmaceutical spending.
resultsOverall, a total of 137 pipeline drugs for RDs were identified, covering 74 indications. The model estimated a total spending on RD treatments equal to €2.08 billion in 2024, corresponding to an average cost of €24,777 per patient. The projection indicates an increase by 1.9% in 2025, 4.0% in 2026, and 7.1% in 2027 compared to 2024. Focusing on orphan designation drugs (n = 115), the 2024 expenditure was estimated at €1.93 billion, with an average patient cost of €22,984. The introduction of new orphan drugs is expected to drive further increases in spending by 1.1% in 2025, 2.2% in 2026, and 3.7% in 2027.
conclusionsThe results underscore the growing financial impact of orphan drugs on Italy's healthcare budget. This analysis offers a quantitative projection of the resources required to ensure continued access to innovative therapies for RDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.